S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Horizon Therapeutics Public Stock Forecast, Price & News

-0.37 (-0.35%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
783,882 shs
Average Volume
1.58 million shs
Market Capitalization
$23.70 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

Horizon Therapeutics Public logo

About Horizon Therapeutics Public

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.


Horizon Therapeutics Public (NASDAQ:HZNP) Shares Gap Up to $107.19
November 19, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.20 billion
Cash Flow
$5.19 per share
Book Value
$19.62 per share


Net Income
$389.80 million
Pretax Margin




Free Float
Market Cap
$23.70 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.36 out of 5 stars

Medical Sector

229th out of 1,391 stocks

Pharmaceutical Preparations Industry

97th out of 669 stocks

Analyst Opinion: 2.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

Is Horizon Therapeutics Public a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 1 sell rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public
or view top-rated stocks.

How has Horizon Therapeutics Public's stock price been impacted by Coronavirus?

Horizon Therapeutics Public's stock was trading at $30.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HZNP stock has increased by 242.5% and is now trading at $104.50.
View which stocks have been most impacted by COVID-19

Are investors shorting Horizon Therapeutics Public?

Horizon Therapeutics Public saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 5,940,000 shares, an increase of 78.9% from the October 14th total of 3,320,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is presently 4.7 days. Currently, 2.7% of the shares of the stock are sold short.
View Horizon Therapeutics Public's Short Interest

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Horizon Therapeutics Public

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) posted its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.54 by $0.21. The biopharmaceutical company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $979.49 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 26.85% and a net margin of 18.66%. The company's revenue was up 62.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.74 earnings per share.
View Horizon Therapeutics Public's earnings history

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public issued an update on its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.16 billion-$3.21 billion, compared to the consensus revenue estimate of $3.12 billion.

What price target have analysts set for HZNP?

10 brokers have issued 12 month price objectives for Horizon Therapeutics Public's stock. Their forecasts range from $100.00 to $168.00. On average, they anticipate Horizon Therapeutics Public's stock price to reach $126.67 in the next year. This suggests a possible upside of 21.2% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public
or view top-rated stocks among Wall Street analysts.

Who are Horizon Therapeutics Public's key executives?

Horizon Therapeutics Public's management team includes the following people:

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public CEO Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among Horizon Therapeutics Public's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.96%), Paulson & CO. Inc. (2.72%), Janus Henderson Group PLC (2.67%), Bank of New York Mellon Corp (1.67%), Voya Investment Management LLC (1.47%) and Renaissance Technologies LLC (1.43%). Company insiders that own Horizon Therapeutics Public stock include Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends for Horizon Therapeutics Public

Which major investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., William Blair Investment Management LLC, Renaissance Technologies LLC, Point72 Asset Management L.P., BlackRock Inc., Eagle Asset Management Inc., Thornburg Investment Management Inc., and Wellington Management Group LLP. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, Vikram Karnani, and William F Daniel.
View insider buying and selling activity for Horizon Therapeutics Public
or view top insider-selling stocks.

Which major investors are buying Horizon Therapeutics Public stock?

HZNP stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Morgan Stanley, American Century Companies Inc., TimesSquare Capital Management LLC, Assenagon Asset Management S.A., Liontrust Investment Partners LLP, Lord Abbett & CO. LLC, and Janus Henderson Group PLC.
View insider buying and selling activity for Horizon Therapeutics Public
or or view top insider-buying stocks.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $104.50.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public has a market capitalization of $23.70 billion and generates $2.20 billion in revenue each year. The biopharmaceutical company earns $389.80 million in net income (profit) each year or $2.32 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

Horizon Therapeutics Public employs 1,395 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

Where are Horizon Therapeutics Public's headquarters?

Horizon Therapeutics Public is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at [email protected], or via fax at 224-383-3001.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.